Evidence map›Paper›PMID 19933379›Full record

ArticleAmerican journal of respiratory cell and molecular biology2010

Fms-like tyrosine kinase 3 ligand decreases T helper type 17 cells and suppressors of cytokine signaling proteins in the lung of house dust mite-sensitized and -challenged mice.

Halvor S McGee, Arthur L Stallworth, Tanupriya Agrawal, Zhifei Shao, Lindsey Lorence, Devendra K Agrawal

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Mechanism of action of M-XQLD treatment for asthma: role of STARD13 in Th17 suppression.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Key mediators in the immunopathogenesis of allergic asthma.International immunopharmacology · 2014
    Review
  9. Article
  10. Article
  11. Clinical view on the importance of dendritic cells in asthma.Expert review of clinical immunology · 2013
    Review
  12. Vitamin D supplementation reduces airway hyperresponsiveness and allergic airway inflammation in a murine model.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2013
    Article
  13. Article
  14. Article
  15. Th17 response is augmented in OVA-induced asthmatic mice exposed to HDM.Medical science monitor : international medical journal of experimental and clinical research · 2011
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Halvor S McGeeCenter for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
Arthur L Stallworth
Tanupriya Agrawal
Zhifei Shao
Lindsey Lorence
Devendra K Agrawal
Creighton University · US

Funding

FLT3-LIGAND, IMMUNOMODULATION AND THERAPY IN ASTHMAR01HL070885 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2004 to 2008
$1.1M
NHLBI NIH HHS R01HL070885
6 · The paper itself

Abstract

We previously reported that Fms-like tyrosine kinase 3 ligand (Flt3-L) reversed airway hyperresponsiveness (AHR) and airway inflammation, and increased the number of regulatory CD11c(high)CD8α(high)CD11b(low) dendritic cells and CD4(+)CD25(+)ICOS(+)Foxp3(+)IL-10(+) T-regulatory cells in the lung of allergen-sensitized and -challenged mice. In this study, we evaluated the effect of Flt3-L on Th17 cells and expression of suppressors of cytokine signaling (SOCS) proteins in the lungs of house dust mite (HDM)-sensitized and -challenged mice. BALB/c mice were sensitized and challenged with HDM, and AHR to methacholine was established. Mice were treated with Flt3-L (5 μg, intraperitoneal) daily for 10 days. Levels of IL-4, -5, -6, -8, and -13, and transforming growth factor (TGF)-β in the bronchoalveolar lavage fluid (BALF) were examined by ELISA. Flt3-L treatment reversed existing AHR to methacholine and substantially decreased eosinophils, neutrophils, IL-5, -6, -8, and IL-13, and TGF-β levels in the BALF. HDM-sensitized and -challenged mice showed a significant increase in lung CD4(+)IL-17(+)IL-23R(+)CD25⁻ T cells with high expression of retinoic acid-related orphan receptor (ROR)-γt transcripts. However, administration of Flt3-L substantially decreased the number of lung CD4(+)IL-17(+)IL-23R(+)CD25⁻ T cells, with significantly decreased expression of ROR-γt mRNA in these cells. HDM sensitization caused a significant increase in the expression of SOCS-1, -3, and -5 in the lung. Flt3-L treatment abolished the increase in SOCS-1 and SOCS-3 proteins, whereas SOCS-5 expression was significantly reduced. These data suggest that the therapeutic effect of Flt3-L in reversing the hallmarks of allergic asthma in a mouse model is mediated by decreasing IL-6 and TGF-β levels in the BALF, which, in turn, decrease CD4(+)IL-17(+)IL-23R(+)ROR-γt(+)CD25⁻ T cells and the expression of SOCS-1 and SOCS-3 in the lung of HDM-sensitized and -challenged mice.

Indexed as

ImmunizationAnimalsBronchial HyperreactivityBronchoalveolar Lavage FluidCD4 AntigensCell CountCell SeparationCytokinesGene Expression RegulationInterleukin-2 Receptor alpha SubunitLungMembrane ProteinsMethacholine ChlorideMiceMice, Inbred BALB CNuclear Receptor Subfamily 1, Group F, Member 3CD4 AntigensCytokinesflt3 ligand proteinInterleukin-2 Receptor alpha SubunitMembrane ProteinsMethacholine ChlorideNuclear Receptor Subfamily 1, Group F, Member 3Receptors, InterleukinRNA, MessengerSuppressor of Cytokine Signaling Proteins

Identifiers

PMID19933379
PMCPMC2970852
OpenAlexW2064793955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.